Shanghai Cell Therapy nets nearly $77m in Series D1 round

Shanghai Cell Therapy nets nearly $77m in Series D1 round

Artist impression of an immune system T-cell.

Shanghai Cell Therapy Group has secured nearly 500 million yuan ($76.6 million) in a Series D1 round of financing to advance its R&D, talent recruitment, and clinical trials of product candidates.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter